MedAdvisor (MDR.AX) Stock Price

Medadvisor Ltd primarily operates in the healthcare industry. As a leading digital medication management company, Medadvisor provides innovative solutions to improve medication adherence and patient engagement. With its advanced platform, Medadvisor integrates with various pharmacies, healthcare providers, and pharmaceutical companies to simplify medication management for individuals. By leveraging technology, Medadvisor aims to enhance patient outcomes, streamline workflows, and promote efficient healthcare delivery. With its strong presence in the healthcare sector, Medadvisor is committed to revolutionizing the way medication is managed and improving the overall patient experience.

The main competitors of Medadvisor Ltd in the market are various companies that provide similar services in the healthcare technology sector. Some notable competitors include Fred IT, Mediserve, and DoseMe. These companies also offer innovative solutions and platforms to enhance patient medication management and improve overall healthcare outcomes. Medadvisor Ltd faces stiff competition in the market, but its strong track record, extensive customer base, and continuous product development strategies position it as a leading player in the healthcare technology industry.

MedAdvisor Ltd is a leading digital medication management company based in Australia. Established in 2010, MedAdvisor has rapidly grown to become a trusted platform for individuals and healthcare providers to manage medications. The company's innovative applications offer features such as prescription management, medication reminders, and real-time adherence monitoring. MedAdvisor also collaborates with pharmacies and pharmaceutical manufacturers to enhance medication adherence and health outcomes. With a focus on patient-centric solutions, MedAdvisor aims to streamline medication management and empower individuals in making informed decisions about their healthcare. MedAdvisor Ltd continues to expand its reach and influence in the healthcare industry, delivering essential digital solutions for improved medication adherence.

Medadvisor Ltd has achieved several significant milestones. The company successfully listed on the Australian Securities Exchange (ASX) in 2015, marking a major achievement in its corporate journey. In 2016, Medadvisor launched an innovative medication adherence platform, which has revolutionized the way patients manage their prescriptions and health. The company has rapidly expanded its user base, reaching over 3 million users in 2021. Medadvisor has also formed strategic partnerships with leading pharmacy groups and healthcare providers, enhancing its market presence and credibility. Additionally, Medadvisor has consistently demonstrated strong revenue growth and continuous technological advancements, solidifying its position as a prominent player in the healthcare technology sector.

Medadvisor Ltd is primarily present in Australia.

Medadvisor Ltd represents the values of innovation, efficiency, and patient-centered care. Their corporate philosophy is centered around leveraging technology to improve medication adherence and patient outcomes. With a focus on providing convenient and accessible healthcare solutions, Medadvisor aims to empower individuals to take control of their health and medication management. Through their user-friendly platform and comprehensive medication management system, Medadvisor strives to simplify and enhance the patient experience. By integrating various healthcare partners, Medadvisor promotes collaboration and seamless communication among healthcare professionals, patients, and pharmacies. Through their commitment to advancing healthcare solutions, Medadvisor Ltd is dedicated to improving overall patient well-being.

8 analysts currently rate the MedAdvisor stock: 0 recommend buying, 4 holding and 4 selling. For 2026, analysts expect MedAdvisor to generate revenue of 110.67 M AUD and earnings per share of 0.00 AUD.

MedAdvisor Analyst Price Targets 2026

Converted at the current exchange rate, the MedAdvisor share trades at 0.01 EUR (0.02 AUD).

Medadvisor Ltd is an Australian company specializing in digital medication management and patient support in adhering to medication plans. Their business model includes a patient app, a software solution for medical professionals, and a drug database. The Medadvisor app allows patients to manage their medications easily and sends reminders for dosages and times. It also informs users of potential medication interactions and health risks. The company provides medical professionals with a tool to monitor patient compliance with medication prescriptions. The drug database offers detailed information on medications, including ingredients, uses, dosages, and applications. Medadvisor works closely with hospitals, pharmacies, and drug manufacturers to enhance patient and professional networking. Overall, Medadvisor offers a practical solution for patients, professionals, and drug manufacturers using modern technology and strict data privacy standards.

The expected revenue of MedAdvisor is 110.67 M AUD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of MedAdvisor is 282,782.02 AUD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of MedAdvisor is currently 38.00. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the MedAdvisor stock.

The price-to-sales ratio (P/S) of MedAdvisor is currently 0.10. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the MedAdvisor stock.

The Eulerpool Quality Score for MedAdvisor is 3/10.

The ISIN of MedAdvisor is AU000000MDR6. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of MedAdvisor is MDR.AX. The ticker symbol is used to trade MedAdvisor shares on the stock exchange.